Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Citius Oncology, Inc. (CTOR : NSDQ)

• Company Description    Citius Oncology Inc. platform to develop and commercialize novel targeted oncology therapies. The company is seeking approval from the U.S. Food and Drug Administration of LYMPHIR(TM) for an orphan indication in the treatment of persistent or recurrent cutaneous T-cell lymphoma, a rare form of non-Hodgkin lymphoma. Citius Oncology Inc., formerly known as TenX Keane Acquisition, is based in New York. Number of Employees:

• Price / Volume Information    Yesterday's Closing Price: $0.84 Daily Weekly Monthly 20 Day Moving Average: 90,548 shares Shares Outstanding: 92.98 (millions) Market Capitalization: $78.09 (millions) Beta: 3.56 52 Week High: $6.19 52 Week Low: $0.49 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -14.10% -18.30% 12 Week -22.94% -28.77% Year To Date -16.01% -23.78%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 11 COMMERCE DRIVE 1ST FLOOR - CRANFORD,NJ 07016 USA ph: 908-967-6677 fax: - ir@citiusonc.com http://www.citiusonc.com

• General Corporate Information    Officers Leonard Mazur - Chief Executive Officer; Chairman and Director Jaime Bartushak - Chief Financial Officer and Treasurer Myron Holubiak - Secretary and Director Suren Dutia - Director Eugene Holuka - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 17331Y109 SIC: 2834 Fiscal Year Fiscal Year End: September Last Reported Quarter: 03/01/26 Next Expected EPS Date: 08/11/26 Share - Related Items Shares Outstanding: 92.98 Most Recent Split Date: (:1) Beta: 3.56 Market Capitalization: $78.09 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio: Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/11/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 2.21 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -145.45% vs. Previous Quarter: -350.00% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -57.73% ROE 03/31/26 - -99.47 12/31/25 - -55.19 09/30/25 - -64.24 ROA 03/31/26 - -42.16 12/31/25 - -23.99 09/30/25 - -26.44 Current Ratio 03/31/26 - 0.50 12/31/25 - 0.83 09/30/25 - 0.56 Quick Ratio 03/31/26 - - 12/31/25 - 0.32 09/30/25 - 0.11 Operating Margin 03/31/26 - - 12/31/25 - - 09/30/25 - - Net Margin 03/31/26 - - 12/31/25 - - 09/30/25 - - Pre-Tax Margin 03/31/26 - -747.62 12/31/25 - -572.49 09/30/25 - - Book Value 03/31/26 - 0.38 12/31/25 - 0.66 09/30/25 - 0.54 Inventory Turnover 03/31/26 - 0.05 12/31/25 - 0.04 09/30/25 - 0.00 Debt-to-Equity 03/31/26 - 0.11 12/31/25 - 0.07 09/30/25 - 0.08 Debt-to-Capital 03/31/26 - 9.73 12/31/25 - 6.11 09/30/25 - 7.81

Powered by Zacks Investment Research ©